The Immune Tolerance Network (ITN), Benaroya Research Institute at Virginia Mason’s (BRI’s) largest research program, is an international network for clinical research in transplantation, allergy, autoimmune diseases and type 1 diabetes. ITN’s mission is to develop therapeutic strategies to reprogram the immune system, while avoiding the risks associated with traditional immunosuppressants. ITN develops and conducts clinical trials through partnerships with academic, governmental and pharmaceutical researchers, focusing on high-impact innovative studies with the goal of improving the lives of people with immune-related diseases.

**Funded by NIH**

The ITN receives approximately $30 million per year for clinical and laboratory research projects, funded primarily by a grant awarded to BRI from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH).

**Program Director**

Gerald T. Nepom, MD, PhD BRI founder and former director

---

**ITN Areas of Study**

- **Allergy & Asthma**  
  Achieve durable desensitization to allergen exposure
- **Autoimmune Disease**  
  Identify therapies to achieve durable clinical remission of autoimmune disease
- **Organ Transplant**  
  Induce tolerance of transplanted organs without lifelong immunosuppression
- **Type 1 Diabetes**  
  Identify therapies that preserve beta cell function

To learn more, visit ImmuneTolerance.org

---

**Clinical study sites**

75 / 250+

**Patients enrolled**

3500+

**Clinical specimens**

700+ THOUSAND
CONSIDER VOLUNTEERING

Participating in a clinical trial is a brave and selfless act. While the outcome of each trial is unknown, ITN’s approach to pairing clinical trials with mechanistic laboratory research makes sure that we learn something from every clinical trial to improve the screening, diagnosis, treatment and prevention of disease — now and on into the future.

Benefits for participants in clinical trials include:

- playing a more active role in their own health care,
- gaining access to new research treatments before they are widely available, and
- helping others by contributing to medical research.

For everyone, however, it is a very personal decision and one that requires careful thought. To learn more, visit ImmuneTolerance.org.

JOIN US

Benaroya Research Institute at Virginia Mason (BRI) is an independent, nonprofit biomedical research institute with a focus on understanding diseases of the immune system. A leader of collaborative initiatives such as the Immune Tolerance Network and Type 1 Diabetes TrialNet, BRI frequently partners with global research institutes, pharmaceutical and biotech companies.

Get More Information

Visit BenaroyaResearch.org and sign up to receive research updates.

Follow stories on the Autoimmune Life blog at BenaroyaResearch.org/blog

Partner in Discovery

We need volunteer donors with and without disease.

BRI researchers work with hundreds of physicians and patients through biorepositories and clinical trials—all focused on improving human health.

Follow us

Donate

To support lifesaving medical research visit: BenaroyaResearch.org/donate-now

Register to donate to a biorepository at BenaroyaResearch.org/bio